Translations by: The LUMC team, particularly Frans van Nieuwpoort
Position title
Principal Scientist, Head of Genetic Epidemiology Lab
Prof of Genetic Epidemiology
Education / training
Institution and location: Bristol University, England Degree: BSc Year(s): 1974 Field of study: Mathematics & Statistics
Institution and location: Bristol University, England Degree: MSc Year(s): 1976 Field of study: Mathematics & Statistics
Institution and location: Sheffield University Degree: PhD Year(s): 1978 Field of study: Probability & Statistics
Professional Experience
1986–1989 Associate Professor, Department of Medical Informatics, University of Utah, Salt Lake City, Utah
1989–present Head of Laboratory, Imperial Cancer Research Fund, Leeds
1994–2000 Professor of Genetic Epidemiology Applied to Cancer, University of Leeds
2000–present Cancer Research UK Professor of Genetic Epidemiology, University of Leeds
Professional committees
1978-present Membership of approximately 50 Ad Hoc USA National Institutes of Health review committees
1987-1996 Genetic Analysis Workshop Committee
1986-1989 American Society of Human Genetics Program Committee
1989-present Steering Committee, UK Cancer Family Study Group
1990-present UKCCCR Familial Ovarian Cancer Registry
1991-present Advisor to Department of Health for Nuclear Industry Family Study
1995-1999 MRC MCMB member
1997-2000 EACR Council Member
1997-present Advisor to NCI (USA) Committee on Familial Colorectal Cancer Studies
1998-present CRC Grants Committee member
1998-present Member of Department of Health Committee Genetic Advisors to Insurance Committee
2001-present Member of Telethon Scientific Committee
Awards
1990 The Royal Society of Medicine (New York) SmithKline Beecham Fellow
1993 Carter Medal from The British Society of Human Genetics
1996 Boerhaave Medal for Contributions to Genetic Epidemiology
2003 President of The International Genetic Epidemiology Society
Publications
Cannon-Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatouspolyps and associated colorectal cancers. N Engl J Med Sep 1; 319(9), 533-7, 1988
Cannon-Albright LA, Thomas TC, Bishop DT, Skolnick MH, Burt RW. Characteristics of familial colon cancer in a large populationdata base. Cancer Nov 1; 64 (9), 1971-5, 1989
Cannon-Albright LA, Bishop DT, Samowitz W, DiSario JA, Lee R, Burt RW. Colonic polyps in an unselected population: prevalence, characteristics, and associations. Am J Gastroenterol. Jun 89(6), 827-31, 1994
Bishop DT. Proximal and progressive: adenomas in HNPCC. GUT; 50: 291-292, 2002.
Sachse, C., Smith G, Wilkie MJV, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT, Wolf RC and the Colorectal Cancer Study Group. "A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23(11): 1839-49, 2002.
Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, dos Santos Silva I, Swerdlow AJ, Bishop DT,Newton Bishop JA. An assessment of the CDKN2A variant ALA148THR as a nevus/melanoma susceptibility allele. JID. 119: 961-965, 2002.
Bishop DT, Demenais F, Goldstein AM, Bergman W, Newton Bishop J, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hannson J, Harland M, Hayward N, Holland EA, Mann GH, Mantelli M, Nancarrow D, Platz A, Tucker MA, The Melanoma Genetics Consortium. Geographical variation in the penetrance of CDKN2A mutations for melanoma. JNCI: 94(12); 894-903,2002.
Jenkins MA, Baglietto L, Dite GS, Jolley DJ, Southey MC, Whitty J, Mead LJ, St John DJB Macrae FA, Bishop DT, Venter DJ, Giles, GG, Hopper JL. After hMSH2 and hMLH1 what next? Analysis of three-generational, population-based, early-onset colorectal cancer families. Int J Ca 102, 166-171, 2002.
McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators (inc Bishop DT), Easton DF, Eeles RA, HowellMA. Influence of cytokine gene polymorphisms on the development of prostate cancer. Ca Research, 62: 3369-3372, 2002.
Meitz JC, Edwards SM, Easton DF, Murkin A, Arden-Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton MR, Houlston RS, The Cancer Research UK/BPG UK Familial Prostate Cancer Study Collaborators (inc Bishop DT), Eeles RA. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. B J Ca, 87: 905-908, 2002.
Kote-Jarai Z, Durocher F, Edwards SM, Hamoudi R, Jackson RA, Arden-Jones A, Murkin A, Dearnaley DP, Kirby R, Houlston R, The CRC/BPG UK Familial Prostate Cancer Collaborators (inc Bishop DT), Easton DF, Eeles R. Association between the GCG polymorphism of the selenium dependent CPX1 gene and the risk of young onset prostate cancer. Prostate Ca & ProstaticDisease, 5: 189-192, 2002.
Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot J, Coxhead J, Garner RC, Steele RJC, Wolf CR, The Colorectal CancerStudy Group (inc BishopDT). Mutations in PAC, Kirsten-ras, and p53 – alternative genetic pathways to colorectal cancer. PNAS. 99 (14) 9433-38 2002
Collaborative Group on Hormonal Factors in Breast Cancer (inc Bishop DT). Breast cancer and breastfeeding: collaborativeReanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet, 360: 187-195, 2002.
Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, Augustsson K, Wolf CR, Bishop DT, Forman D and the Colorectal Cancer Study Group. Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis, 24(2): 275-282, 2003.
Saunders CL, Bishop DT, Barrett JH. Sample size calculations for main effects and interactions in case-control studies using Stata’snchi1 and npnchi2 functions. The Stata Journal, 3(1): 47-56, 2003
Zauber NP, Sabbath-Solitare M, Marotta SP, Bishop DT. The characterization of somatic APC mutations in colonic adenomas and carcinomas in Ashkenazi Jews with the APC I1307K variant using linkage disequilibrium. J Pathology, 199(2): 146-151, 2003.
Barrett JH, Gaut R, Wachsmuth R, Newton Bishop JA, Bishop DT. Linkage and association analysis of nevus density and the region containing the melanoma gene CDKN2A in a study of UK twins. British Journal of Cancer, 88: 1920-1924, 2003
Bevan S, Edwards SM, Ardern-Jones A, Dowe A, Southgate C, Dearnaley D, Easton DF, Houlston RS, Eeles RA and theCRC/BPGUK Familial Prostate cancer Study Collaborators (inc DTB). Germline mutations in fumarate hydratase (FH) do notpredispose to prostate cancer. Prostate Cancer & Prostatic Diseases, 6: 12-14, 2003.
Crockford GP, Bishop DT, Barrett JH. Segregation analysis comparing liability and quantitative trait models for hypertension using the Genetic Analysis Workshop 13 simulated data. BMC Genetics 4 (Suppl 1):S79, 2003
Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73:301-13, 2003
Mathers JC, Mickleburgh I, Chapman PC, Bishop DT, Burn J. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. Proc Nutr Soc 62:51-7, 2003
Zauber NP, Sabbath-Solitare M, Marotta SP, Bishop DT. The Adenomatous Polyposis Coli (APC) gene microsatellite marker D5S1385 is equally informative for loss of heterozygosity as the marker D5S346. Exp Mol Pathol 75:144-7, 2003
Zauber P, Sabbath-Solitare M, Marotta SP, Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. J Clin Pathol: Mol Pathol56:137-40, 2003
Dorsch MF, Barrett JH, Lawrance RA, Maqbool A, Durham NP, Ellis S, Samani NJ, Bishop DT, Ball SG, Balmforth AJ, Hall AS. Premature coronary artery disease shows no evidence of linkage to loci encoding for tissue inhibitors of matrix metalloproteinases. J Hum Genet 48: 508-513, 2003
Rapley E, Crockford GP, Easton D, Stratton M, Bishop D, Consortium at ITCL. Localisation of susceptibility genes for familial testicular germ cell tumour. Acta Pathologica, Microbiologica, Immunologica Scandanavia APMIS. 111:128-133, 2003
Bertram CG, Gaut RM, Barrett JH, Randerson-Moor J, Whitaker L, Turner F, Bataille V, dos Santos Silva I, Swedlow AJ, BishopDT, Newton Bishop JA. An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype. J Invest Dermatol 122 (2):429-432, 2004
Bishop (PI) 01/09/99 – 31/08/04, 01/09/04 – 31/08/09 Cancer Research UK Core Funding for Genetic Epidemiology
This support covers studies of genetic epidemiology of bowel cancer, melanoma and testicular cancer. No support for genotyping is included in this funding. Role: PI
Bishop (PI) 01/08/03 – 31/07/06 Cancer Research UK Reduction Of Bowel Cancer Risk After HRT
This funding supports one interviewer (to be named) who will assist in the recruitment of colorectal cancer cases and controls for the epidemiological study of HRT. This funding also provides travel expenses. Role: PI Easton (PI) 01/04/98 – 31/07/04
Cancer Research Campaign (Subsequently Cancer Research UK) Epidemiological Study Of BRCA1 And BRCA2 Mutation Carriers (EMBRACE) This funding supports the recruitment of persons into the Cohort Study of BRCA1 and BRCA2 carriers. None of the funding comes to Leeds as Doug Easton’s Group conducts all of the coordination of this study Role: Co-investigator
Kiltie, Bishop (PI’s) 01/08/03 – 31/07/05 Cancer Research UK Molecular Epidemiology Of DNA Repair And Bladder Cancer
This funding supports a Clinical Research Fellow (Mr Sek Sei) to recruit bladder cancer cases and controls and to genotype those samples for polymorphisms in DNA repair genes. We provide statistical support to this group. Role: (PI) Elder (PI) 01/09/01 – 30/08/06
NIH/National Cancer Institute Genetic Epidemiology of Melanoma This funding supports 3.7 interviewers to recruit into the case-control study of melanoma, a statistician from 09/04 – 08/06 and a laboratory technician from 01/03 – 06/05. Role: Co-investigator Burn (PI) 01/01/02 – 31/01/08
Medical Research Council The Colorectal Adenoma/Carcinoma Prevention Programme 2 (CAPP2). A Randomised Controlled Trial Of Colorectal Polyp And Cancer Prevention Using Aspirin And Resistant Starch In Carriers Of Hereditary Non-Polyposis Colon Cancer (HNPCC) This funding pays for recruitment into the clinical trial. We act as the randomisation centre for this study. No funding comes directly to Leeds. Role: Co-investigator Wolf (PI) 01/04/01 – 20/06/05
Food Standards Agency The Influence of Diet and Genetic Polymorphism on Susceptibility to Colorectal adenomas This funding supports dietary assessment and genotyping for persons found to have colorectal adenomas in a Scottish study of the feasibility of implementing faecal occult blood testing in the general population. Role: Co-investigator
Houlston, Tomlinson (PI’s) 01/10/02 – 30/09/07 Digestive Disorders Foundation Identification and Epidemiological Characterisation of Low Penetrance Colorectal Cancer Genes
This funding supports the collection of families for linkage mapping and association studies for colorectal cancer based on case-control studies where cases are chosen to have a family history. This funds one research Nurse/Interviewer in Leeds (Mrs Sandra Hanby employed until 30 September 2005) and in two other centres as well as paying for genotyping costs. Role: Co-investigator
Completed Research Support
Bishop (PI) 02/12/99 – 31/03/04 National Lottery Charities Board (subsequently Community Fund) The British Familial Cancer Record
This funding supports a Research Co-ordinator in Leeds and five others around the country. The funding supports research into the outcomes of screening surveillance for women with an increased risk of breast cancer. Role:PIBall (PI) 01/10/01 – 31/12/03
British Heart Foundation The BHF Family Heart Study This funding supports an affected sib-pair study of early myocardial infarction and supports a statistician to provide analyses of the linkage study (Dr Kevin Walters). Role:Co-investigatorNewton Bishop (PI) 01/06/00 – 30/06/03
Cancer research UK A Cohort Study Of Melanoma: The Genetics And Epidemiology Of Relapse: A Pilot Study This funding supports one interviewer (Mrs Susan Leake) to recruit cases into the Melanoma Cohort Study and also provides travel expenses Role: Co-investigatorCade (PI) 01/04/00 – 30/03/03
Ministry of Agriculture, Fisheries and Food (subsequently FSA) Influence Of Genetic Mutations On Iron Status Linked To Dietary Intake: From The UK Women’s Cohort Study Role:Co-investigator
Newton Bishop 01/10/00 – 31/03/03 Skin Cancer Research Fund (ScaRF) An Epidemiological Study Of Late Relapsing Melanoma Role: Co-investigatorHall (PI) 01/05/01 – 30/04/03
Medical Research Council The Acute Coronary Event DNA Library Project: A National Collection Of DNA From 2000 Families Affected By Premature Coronary Artery Disease (ADLIB) Role: Co-investigator
